Table 1.
Subject Inclusions
| Time Point | Action | ID Group n (%) |
IM Group n (%) |
Total n (%) |
|---|---|---|---|---|
| D0 | Blood sampling and vaccination | 115 (100.0) | 100 (100.0) | 215 (100.0) |
| RIG administered | 14 (12.2) | 15 (15.0) | 29 (13.5) | |
| D3 | Vaccination | 114 (99.1) | 99 (99.0) | 213 (99.1) |
| D7 | Blood sampling and vaccination | 113 (98.2) | 99 (99.0) | 212 (98.6) |
| D14 | Blood sampling | 112 (97.4) | 99 (99.0) | 211 (98.1) |
| Vaccination | NA | 99 (99.0) | NA | |
| D28 | Blood samplinga | 112 (97.4) | 98 (98.0) | 210 (97.7) |
| M6 | Survival follow-up | 112 (97.4) | 98 (98.0) | 210 (97.7) |
| Loss of follow-upb | 1 (0.9) | 0 (0.0) | 1 (0.5) | |
| Reachable and healthyb | 111 (99.1) | 98 (100.0) | 209 (99.5) |
Abbreviations: NA, not applicable; RIG, rabies immunoglobulin.
Drop outs until D28: 2 subjects refused later blood collection at D3, 1 at D7, 1 died in road accident before D14 blood collection, 1 subject could not attend D28 sample collection due to COVID-19 lock-down.
Including only individuals that where present through the follow-up until D28.